Almorexant
Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011.
Wikipage redirect
primaryTopic
Almorexant
Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011.
has abstract
Almorexant (INN, codenamed ACT ...... was abandoned in January 2011.
@en
ATC prefix
CAS number
871224-64-5
FDA UNII code
9KCW39P2EI
IUPAC name
(2R)-2-[(1S)- 6,7-Dimethoxy-1- ...... yl]-N-methyl-2-phenylacetamide
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
19,451,365
Wikipage revision ID
742,528,501
ChEMBL
ChemSpiderID
21,377,865
IUPHAR ligand
metabolism
molecular weight
routes of administration
smiles
CNC[C@@H]N2CCC3=CCOC
StdInChIKey
DKMACHNQISHMDN-RPLLCQBOSA-N
Verifiedfields
verifiedrevid
477,318,417
Watchedfields
subject
hypernym
comment
Almorexant (INN, codenamed ACT ...... was abandoned in January 2011.
@en
label
Almorexant
@en